About VarmX
To revolutionize the treatment of severe bleeding through a fast, safe, and effective medicine
VarmX’s VMX-C001 is being developed to facilitate the fast, safe, and effective treatment of severe bleeds in patients that are taking Factor Xa DOACS. In addition, it enables patients on this class of blood thinners to undergo emergency surgery reducing the risk of bleeding associated with FXa DOACs.
A team dedicated to making a difference
VarmX was founded by Professor Pieter Reitsma, who was previously head of the department of Thrombosis and Hemostasis at Leiden University Medical Centre (LUMC). He is a world leading expert in the genetics of Hemostasis and Thrombosis having co-discovered Factor V Leiden, a genetic blood clotting disorder.
Together with our experienced management team, reputable board of directors, and a network of international scientific advisors, VarmX’s purpose is to make a significant impact in the field of coagulation.
Our investors
We are proud to have the backing of a strong syndicate of investors, including Sound Bioventures, EIC, EQT Life Sciences (formerly LSP), Inkef, Lundbeckfonden BioCapital, Ysios Capital, BioGeneration Ventures and InnovationQuarter. These investors have deep knowledge, expertise, and resources, and share our vision of revolutionizing the field of coagulation therapy by providing safe and effective treatments to patients. Their support gives us the confidence to strive to deliver innovative medical solutions.
